TMCI Quote, Financials, Valuation and Earnings

Insulet has a net margin of -30.29% compared to Treace Medical Concepts's net margin of 6.22%. Treace Medical Concepts's return on equity of -47.17% beat Insulet's return on equity of 36.9%.

Treace Medical Concepts has a consensus price target of $9.73, signalling upside risk potential of 71.58%. On the other hand Insulet has an analysts' consensus of $334.74 which suggests that it could grow by 9.89%. Given that Treace Medical Concepts has higher upside potential than Insulet, analysts believe Treace Medical Concepts is more attractive than Insulet.

Treace Medical Concepts has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Insulet has a beta of 1.375, suggesting its more volatile than the S&P 500 by 37.475%.

Treace Medical Concepts has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insulet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Treace Medical Concepts pays -- of its earnings as a dividend. Insulet pays out -- of its earnings as a dividend.

Treace Medical Concepts quarterly revenues are $52.6M, which are smaller than Insulet quarterly revenues of $569M. Treace Medical Concepts's net income of -$15.9M is lower than Insulet's net income of $35.4M. Notably, Treace Medical Concepts's price-to-earnings ratio is -- while Insulet's PE ratio is 54.79x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Treace Medical Concepts is 1.68x versus 10.25x for Insulet. Usually stocks with elevated PS ratios are considered overvalued.

RxSight has a net margin of -30.29% compared to Treace Medical Concepts's net margin of -21.61%. Treace Medical Concepts's return on equity of -47.17% beat RxSight's return on equity of -10.39%.

Treace Medical Concepts has a consensus price target of $9.73, signalling upside risk potential of 71.58%. On the other hand RxSight has an analysts' consensus of $21.18 which suggests that it could grow by 49.06%. Given that Treace Medical Concepts has higher upside potential than RxSight, analysts believe Treace Medical Concepts is more attractive than RxSight.

Treace Medical Concepts has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison RxSight has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Treace Medical Concepts has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. RxSight offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Treace Medical Concepts pays -- of its earnings as a dividend. RxSight pays out -- of its earnings as a dividend.

Treace Medical Concepts quarterly revenues are $52.6M, which are larger than RxSight quarterly revenues of $37.9M. Treace Medical Concepts's net income of -$15.9M is lower than RxSight's net income of -$8.2M. Notably, Treace Medical Concepts's price-to-earnings ratio is -- while RxSight's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Treace Medical Concepts is 1.68x versus 3.81x for RxSight. Usually stocks with elevated PS ratios are considered overvalued.

West Pharmaceutical Services has a net margin of -30.29% compared to Treace Medical Concepts's net margin of 12.87%. Treace Medical Concepts's return on equity of -47.17% beat West Pharmaceutical Services's return on equity of 17.47%.

Treace Medical Concepts has a consensus price target of $9.73, signalling upside risk potential of 71.58%. On the other hand West Pharmaceutical Services has an analysts' consensus of $281.92 which suggests that it could grow by 27.04%. Given that Treace Medical Concepts has higher upside potential than West Pharmaceutical Services, analysts believe Treace Medical Concepts is more attractive than West Pharmaceutical Services.

Treace Medical Concepts has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison West Pharmaceutical Services has a beta of 1.092, suggesting its more volatile than the S&P 500 by 9.216%.

Treace Medical Concepts has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. West Pharmaceutical Services offers a yield of 0.37% to investors and pays a quarterly dividend of $0.21 per share. Treace Medical Concepts pays -- of its earnings as a dividend. West Pharmaceutical Services pays out 12% of its earnings as a dividend. West Pharmaceutical Services's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Treace Medical Concepts quarterly revenues are $52.6M, which are smaller than West Pharmaceutical Services quarterly revenues of $698M. Treace Medical Concepts's net income of -$15.9M is lower than West Pharmaceutical Services's net income of $89.8M. Notably, Treace Medical Concepts's price-to-earnings ratio is -- while West Pharmaceutical Services's PE ratio is 34.84x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Treace Medical Concepts is 1.68x versus 5.62x for West Pharmaceutical Services. Usually stocks with elevated PS ratios are considered overvalued.

Zimmer Biomet Holdings has a net margin of -30.29% compared to Treace Medical Concepts's net margin of 9.53%. Treace Medical Concepts's return on equity of -47.17% beat Zimmer Biomet Holdings's return on equity of 7.29%.

Treace Medical Concepts has a consensus price target of $9.73, signalling upside risk potential of 71.58%. On the other hand Zimmer Biomet Holdings has an analysts' consensus of $107.50 which suggests that it could grow by 17.77%. Given that Treace Medical Concepts has higher upside potential than Zimmer Biomet Holdings, analysts believe Treace Medical Concepts is more attractive than Zimmer Biomet Holdings.

Treace Medical Concepts has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Zimmer Biomet Holdings has a beta of 0.717, suggesting its less volatile than the S&P 500 by 28.281%.

Treace Medical Concepts has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zimmer Biomet Holdings offers a yield of 1.05% to investors and pays a quarterly dividend of $0.24 per share. Treace Medical Concepts pays -- of its earnings as a dividend. Zimmer Biomet Holdings pays out 21.69% of its earnings as a dividend. Zimmer Biomet Holdings's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Treace Medical Concepts quarterly revenues are $52.6M, which are smaller than Zimmer Biomet Holdings quarterly revenues of $1.9B. Treace Medical Concepts's net income of -$15.9M is lower than Zimmer Biomet Holdings's net income of $182M. Notably, Treace Medical Concepts's price-to-earnings ratio is -- while Zimmer Biomet Holdings's PE ratio is 20.19x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Treace Medical Concepts is 1.68x versus 2.40x for Zimmer Biomet Holdings. Usually stocks with elevated PS ratios are considered overvalued.